Delcath Systems Schedules Conference Call to Report 2021 Third Quarter Financial Results

Rhea-AI Summary

Delcath Systems (DCTH) announced a conference call on November 9, 2021, at 8:30 AM ET to discuss its Q3 2021 results ending September 30, 2021. The company specializes in interventional oncology, focusing on liver cancers through its proprietary percutaneous hepatic perfusion (PHP) system. In the U.S., it markets the system as HEPZATO KIT, while in Europe, it operates as CHEMOSAT Hepatic Delivery System. Interested parties can join the call via toll-free or international numbers, or stream it online.

Positive

• Delcath's proprietary PHP system is gaining traction in both the U.S. and European markets.
• The upcoming call indicates active communication with investors regarding business performance.

Negative

• Details regarding financial performance for the Q3 2021 are yet to be disclosed, creating uncertainty among investors.

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2021.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: November 9, 2021
Time: 8:30 AM Eastern Time
Toll Free: 888-506-0062; Entry Code: 676028
International: 973-528-0011; Entry Code: 676028

The call will also be available over the Internet and accessible at:

https://www.webcaster4.com/Webcast/Page/2475/43392

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

What is the date and time of Delcath Systems' Q3 2021 results conference call?

The conference call is scheduled for November 9, 2021, at 8:30 AM Eastern Time.

How can I join the Delcath Systems conference call?

You can join via toll-free number 888-506-0062 or international number 973-528-0011, using entry code 676028, or stream it online.

What is the focus of Delcath Systems?

Delcath Systems focuses on interventional oncology, particularly the treatment of primary and metastatic liver cancers.

What is the trade name of Delcath's PHP system in the U.S.?

In the U.S., Delcath's PHP system is marketed as HEPZATO KIT.

What is the trade name of Delcath's PHP system in Europe?

In Europe, it is marketed as CHEMOSAT Hepatic Delivery System.